Ignite Creation Date:
2025-12-24 @ 4:48 PM
Ignite Modification Date:
2025-12-25 @ 2:33 PM
Study NCT ID:
NCT03491150
Status:
TERMINATED
Last Update Posted:
2020-07-13
First Post:
2018-03-15
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Belgium', 'Costa Rica', 'Croatia', 'Czechia', 'Denmark', 'Hungary', 'Portugal', 'South Africa', 'Sweden', 'Ukraine']}, 'conditionBrowseModule': {'meshes': [{'id': 'D000544', 'term': 'Alzheimer Disease'}, {'id': 'D003704', 'term': 'Dementia'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D024801', 'term': 'Tauopathies'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C573372', 'term': 'crenezumab'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'genentech@druginfo.com', 'phone': '800 821-8590', 'title': 'Medical Communications', 'organization': 'Hoffmann-La Roche'}, 'certainAgreement': {'otherDetails': "The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.'}}, 'adverseEventsModule': {'timeFrame': 'Baseline up to 16 weeks after the last dose of study drug (up to 54 weeks).', 'eventGroups': [{'id': 'EG000', 'title': 'Parent Placebo', 'description': 'Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).', 'otherNumAtRisk': 76, 'deathsNumAtRisk': 76, 'otherNumAffected': 4, 'seriousNumAtRisk': 76, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG001', 'title': 'Parent Crenezumab', 'description': 'Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).', 'otherNumAtRisk': 73, 'deathsNumAtRisk': 73, 'otherNumAffected': 4, 'seriousNumAtRisk': 73, 'deathsNumAffected': 0, 'seriousNumAffected': 4}], 'otherEvents': [{'term': 'FALL', 'stats': [{'groupId': 'EG000', 'numAtRisk': 76, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 73, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 22.0'}], 'seriousEvents': [{'term': 'OPTIC ISCHAEMIC NEUROPATHY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 76, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 73, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 22.0'}, {'term': 'INCARCERATED INGUINAL HERNIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 76, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 73, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 22.0'}, {'term': 'RECTAL HAEMORRHAGE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 76, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 73, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 22.0'}, {'term': 'PNEUMONIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 76, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 73, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 22.0'}, {'term': 'UROSEPSIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 76, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 73, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 22.0'}, {'term': 'FALL', 'stats': [{'groupId': 'EG000', 'numAtRisk': 76, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 73, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 22.0'}, {'term': 'CEREBROVASCULAR ACCIDENT', 'stats': [{'groupId': 'EG000', 'numAtRisk': 76, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 73, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 22.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '73', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Parent Placebo', 'description': 'Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).'}, {'id': 'OG001', 'title': 'Parent Crenezumab', 'description': 'Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).'}], 'classes': [{'title': 'AEs', 'categories': [{'measurements': [{'value': '32.9', 'groupId': 'OG000'}, {'value': '42.5', 'groupId': 'OG001'}]}]}, {'title': 'SAEs', 'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000'}, {'value': '5.5', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to 16 weeks after the last dose of study drug (up to 54 weeks).', 'description': 'An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety analysis population was defined as all participants who consented to the OLE study, including those who enrolled in the OLE but did not receive open-label treatment.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With Anti-Crenezumab Antibodies', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Parent Placebo', 'description': 'Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).'}, {'id': 'OG001', 'title': 'Parent Crenezumab', 'description': 'Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).'}], 'timeFrame': 'Baseline up to end of study (up to 54 weeks).', 'description': 'Participants were considered positive or negative for ADA based on their baseline and post-baseline sample results. The number and percentage of participants with confirmed positive ADA levels were determined for Crenezumab and Placebo groups. The prevalence of ADA at baseline was calculated as the proportion of participants with confirmed positive ADA levels at baseline relative to the total number of participants with a sample available at baseline. The incidence of treatment-emergent ADAs was determined as the proportion of participants with confirmed post-baseline positive ADAs relative to the total number of participants that had at least one post-baseline sample available for ADA analysis.', 'reportingStatus': 'POSTED', 'populationDescription': 'Please note that for this Outcome Measure, no Participants were evaluated at all as the existing immunogenicity data from a parent study (Study BN29552) showed a low potential of Crenezumab to induce Anti-Drug Antibodies (ADAs).'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Parent Placebo', 'description': 'Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).'}, {'id': 'FG001', 'title': 'Parent Crenezumab', 'description': 'Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '76'}, {'groupId': 'FG001', 'numSubjects': '73'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '76'}, {'groupId': 'FG001', 'numSubjects': '73'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Study Terminated by Sponsor', 'reasons': [{'groupId': 'FG000', 'numSubjects': '74'}, {'groupId': 'FG001', 'numSubjects': '70'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}]}]}], 'recruitmentDetails': 'The study was conducted at 66 centers in 16 countries.', 'preAssignmentDetails': 'A total of 149 participants were enrolled at 66 centers. These 149 participants represented the Safety Analysis population and data for this population is presented here.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'BG000'}, {'value': '73', 'groupId': 'BG001'}, {'value': '149', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Parent Placebo', 'description': 'Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).'}, {'id': 'BG001', 'title': 'Parent Crenezumab', 'description': 'Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '73.8', 'spread': '7.6', 'groupId': 'BG000'}, {'value': '72.0', 'spread': '7.6', 'groupId': 'BG001'}, {'value': '72.9', 'spread': '7.6', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '37', 'groupId': 'BG000'}, {'value': '38', 'groupId': 'BG001'}, {'value': '75', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '39', 'groupId': 'BG000'}, {'value': '35', 'groupId': 'BG001'}, {'value': '74', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Hispanic or Latino', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}]}]}, {'title': 'Not Hispanic or Latino', 'categories': [{'measurements': [{'value': '69', 'groupId': 'BG000'}, {'value': '69', 'groupId': 'BG001'}, {'value': '138', 'groupId': 'BG002'}]}]}, {'title': 'Not Stated', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Asian', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}]}]}, {'title': 'Black or African American', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}, {'title': 'Unknown', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}]}, {'title': 'White', 'categories': [{'measurements': [{'value': '72', 'groupId': 'BG000'}, {'value': '67', 'groupId': 'BG001'}, {'value': '139', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-08-05', 'size': 1462188, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2020-05-26T15:37', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Open Label Extension (OLE)'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 149}}, 'statusModule': {'whyStopped': 'This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2018-04-11', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-06', 'completionDateStruct': {'date': '2019-05-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-06-25', 'studyFirstSubmitDate': '2018-03-15', 'resultsFirstSubmitDate': '2020-05-26', 'studyFirstSubmitQcDate': '2018-04-05', 'lastUpdatePostDateStruct': {'date': '2020-07-13', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-05-26', 'studyFirstPostDateStruct': {'date': '2018-04-09', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2020-06-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-05-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'Baseline up to 16 weeks after the last dose of study drug (up to 54 weeks).', 'description': 'An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.'}, {'measure': 'Percentage of Participants With Anti-Crenezumab Antibodies', 'timeFrame': 'Baseline up to end of study (up to 54 weeks).', 'description': 'Participants were considered positive or negative for ADA based on their baseline and post-baseline sample results. The number and percentage of participants with confirmed positive ADA levels were determined for Crenezumab and Placebo groups. The prevalence of ADA at baseline was calculated as the proportion of participants with confirmed positive ADA levels at baseline relative to the total number of participants with a sample available at baseline. The incidence of treatment-emergent ADAs was determined as the proportion of participants with confirmed post-baseline positive ADAs relative to the total number of participants that had at least one post-baseline sample available for ADA analysis.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Dementia', 'Neurodegenerative Diseases', 'Brain Diseases', 'Central Nervous System Diseases', 'Nervous System Diseases', 'Tauopathies', 'Neurocognitive Disorders', 'Mental Disorders'], 'conditions': ["Alzheimer's Disease"]}, 'descriptionModule': {'briefSummary': 'In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in participants on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Previous participation in Study BN29552 or BN29553 and completion of the Week 105 visit.\n* Able to provide written informed consent by the patient or legally authorized representative, if required.\n* Every effort to have the same caregiver participate throughout the duration of the OLE (Open Label Extension) study who also participated in Study BN29552 or BN29553.\n* Willingness and ability to complete all aspects of the study \\[including MRI (Magnetic Resonance Imaging), lumbar puncture \\[if applicable\\], and PET (Positron Emission Tomography) imaging \\[if applicable\\].\n* Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing.\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a protocol approved contraceptive method and agreement to refrain from donating eggs for at least 8 weeks after last dose.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a protocol approved contraceptive method for at least 8 weeks after last dose.\n\nExclusion Criteria:\n\n* Patients who discontinued treatment permanently in Study BN29552 or BN29553 for safety reasons.\n* Impaired coagulation.\n* Evidence of more than 10 microbleeds and/or ARIA-H (amyloid-related imaging abnormalities-hemosiderin deposition) at the Study BN29552 or BN29553 Week 105 visit, as assessed by central review of MRI.\n* Diagnosed with three recurrent, symptomatic ARIA-E (amyloid-related imaging abnormalities-edema/effusion) events or exacerbations of previous events.\n* Presence of intracranial lesion that could potentially increase the risk of CNS (Central Nervous System) bleeding.\n* At risk of suicide in the opinion of the investigator.\n* Alcohol and/or substance abuse or dependence within the past 2 years and during the study.\n* Inability to tolerate MRI procedures or contraindication to MRI, including, but not limited to, presence of pacemakers not compatible with MRI, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or body that would contraindicate an MRI scan; or any other clinical history or examination finding that, in the judgment of the investigator, would pose a potential hazard in combination with MRI.\n* Pregnant or lactating, or intending to become pregnant during the study.\n* Any other severe or unstable medical condition that, in the opinion of the investigator or Sponsor, could be expected to progress, recur, or change to such an extent that it could put the patient at special risk, bias the assessment of the clinical or mental status of the patient to a significant degree, or interfere with the patient's ability to complete the study assessments.\n* Chronic use of anticoagulants or participation in any other investigational drug treatment trial."}, 'identificationModule': {'nctId': 'NCT03491150', 'acronym': 'CREAD OLE', 'briefTitle': "An Open-Label Crenezumab Study in Participants With Alzheimer's Disease", 'organization': {'class': 'INDUSTRY', 'fullName': 'Hoffmann-La Roche'}, 'officialTitle': "A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease", 'orgStudyIdInfo': {'id': 'BN40031'}, 'secondaryIdInfos': [{'id': '2017-002702-12', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Parent Placebo', 'description': 'Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).', 'interventionNames': ['Drug: Crenezumab']}, {'type': 'EXPERIMENTAL', 'label': 'Parent Crenezumab', 'description': 'Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).', 'interventionNames': ['Drug: Crenezumab']}], 'interventions': [{'name': 'Crenezumab', 'type': 'DRUG', 'otherNames': ['RO5490245'], 'description': 'Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.', 'armGroupLabels': ['Parent Crenezumab', 'Parent Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92663', 'city': 'Newport Beach', 'state': 'California', 'country': 'United States', 'facility': 'Shankle Clinic', 'geoPoint': {'lat': 33.61891, 'lon': -117.92895}}, {'zip': '92374', 'city': 'Redlands', 'state': 'California', 'country': 'United States', 'facility': 'Anderson Clinical Research, Inc.', 'geoPoint': {'lat': 34.05557, 'lon': -117.18254}}, {'zip': '95817', 'city': 'Sacramento', 'state': 'California', 'country': 'United States', 'facility': 'University of California, Davis; Alzheimers Disease Center, Department of Neurology', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'zip': '94158', 'city': 'San Francisco', 'state': 'California', 'country': 'United States', 'facility': 'UCSF - Memory and Aging Center', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '90404', 'city': 'Santa Monica', 'state': 'California', 'country': 'United States', 'facility': 'Neurological Research Inst', 'geoPoint': {'lat': 34.01949, 'lon': -118.49138}}, {'zip': '06810', 'city': 'Danbury', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Associated Neurologists PC - Danbury', 'geoPoint': {'lat': 41.39482, 'lon': -73.45401}}, {'zip': '06510', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Institute for Neurodegenerative Disorders', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '06510', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Yale University School Of Medicine', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '06851', 'city': 'Norwalk', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Research Center for Clinical Studies, Inc.', 'geoPoint': {'lat': 41.1176, 'lon': -73.4079}}, {'zip': '34205', 'city': 'Bradenton', 'state': 'Florida', 'country': 'United States', 'facility': 'Bradenton Research Center', 'geoPoint': {'lat': 27.49893, 'lon': -82.57482}}, {'zip': '33445', 'city': 'Delray Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Brain Matters Research, Inc.', 'geoPoint': {'lat': 26.46146, 'lon': -80.07282}}, {'zip': '33414', 'city': 'Lake Worth', 'state': 'Florida', 'country': 'United States', 'facility': "Alzheimer's Research and Treatment Center", 'geoPoint': {'lat': 26.61708, 'lon': -80.07231}}, {'zip': '34470', 'city': 'Ocala', 'state': 'Florida', 'country': 'United States', 'facility': 'Renstar Medical Research', 'geoPoint': {'lat': 29.1872, 'lon': -82.14009}}, {'zip': '32806', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Bioclinica Research', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '32127', 'city': 'Port Orange', 'state': 'Florida', 'country': 'United States', 'facility': 'Progressive Medical Research', 'geoPoint': {'lat': 29.13832, 'lon': -80.99561}}, {'zip': '33613', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Stedman Clinical Trials, LLC', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30033', 'city': 'Decatur', 'state': 'Georgia', 'country': 'United States', 'facility': 'NeuroStudies.net, LLC', 'geoPoint': {'lat': 33.77483, 'lon': -84.29631}}, {'zip': '60007', 'city': 'Elk Grove Village', 'state': 'Illinois', 'country': 'United States', 'facility': 'Alexian Brothers Neurosci Inst', 'geoPoint': {'lat': 42.00392, 'lon': -87.97035}}, {'zip': '62702', 'city': 'Springfield', 'state': 'Illinois', 'country': 'United States', 'facility': 'Southern Illinois University, School of Medicine', 'geoPoint': {'lat': 39.80172, 'lon': -89.64371}}, {'zip': '66206', 'city': 'Prairie Village', 'state': 'Kansas', 'country': 'United States', 'facility': 'MidAmerica Neuroscience Institute', 'geoPoint': {'lat': 38.99167, 'lon': -94.63357}}, {'zip': '04074', 'city': 'Scarborough', 'state': 'Maine', 'country': 'United States', 'facility': 'MMP Neurology', 'geoPoint': {'lat': 43.57814, 'lon': -70.32172}}, {'zip': '39232', 'city': 'Flowood', 'state': 'Mississippi', 'country': 'United States', 'facility': 'Precise Research Centers', 'geoPoint': {'lat': 32.30959, 'lon': -90.13898}}, {'zip': '07081', 'city': 'Springfield', 'state': 'New Jersey', 'country': 'United States', 'facility': 'The Cognitive and Research Center of New Jersey', 'geoPoint': {'lat': 40.70491, 'lon': -74.31723}}, {'zip': '08755', 'city': 'Toms River', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Advanced Memory Research Institute of NJ', 'geoPoint': {'lat': 39.95373, 'lon': -74.19792}}, {'zip': '28211', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Behavioral Health Research', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '27401', 'city': 'Greensboro', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Guilford Neurologic Associates', 'geoPoint': {'lat': 36.07264, 'lon': -79.79198}}, {'zip': '73112', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Oklahoma Clinical Research', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '97210', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Summit Research Network Inc.', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '19090', 'city': 'Willow Grove', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Abington Neurological Associates', 'geoPoint': {'lat': 40.144, 'lon': -75.11573}}, {'zip': '78757', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'Senior Adults Specialty Research', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '23507', 'city': 'Norfolk', 'state': 'Virginia', 'country': 'United States', 'facility': 'Sentara Medical Group', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'zip': '23294', 'city': 'Richmond', 'state': 'Virginia', 'country': 'United States', 'facility': 'National Clinical Research Inc.-Richmond', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '3081', 'city': 'Heidelberg West', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre', 'geoPoint': {'lat': -37.73922, 'lon': 145.04034}}, {'zip': '6005', 'city': 'West Perth', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'Neurodegenerative Disorders Research; Neurology', 'geoPoint': {'lat': -31.94896, 'lon': 115.84199}}, {'zip': 'N6C 5J1', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Parkwood Hospital; Geriatric Medicine', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'K9H 2P4', 'city': 'Peterborough', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Kawartha Centre - Redefining Healthy Aging', 'geoPoint': {'lat': 44.30012, 'lon': -78.31623}}, {'zip': 'M4G 3E8', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'The Centre for Memory and Aging', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'N4S 5P5', 'city': 'Woodstock', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Devonshire Clinical Research Inc.', 'geoPoint': {'lat': 43.13339, 'lon': -80.7497}}, {'zip': '33100', 'city': 'Tampere', 'country': 'Finland', 'facility': 'Terveystalo Tampere', 'geoPoint': {'lat': 61.49911, 'lon': 23.78712}}, {'zip': '31059', 'city': 'Toulouse Cedec', 'country': 'France', 'facility': 'Hopital La Grave; Place Lange'}, {'zip': '81675', 'city': 'München', 'country': 'Germany', 'facility': 'Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie', 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}}, {'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': 'Prince of Wales Hospital; Dept. of Medicine & Therapeutics', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'zip': '00179', 'city': 'Rome', 'state': 'Lazio', 'country': 'Italy', 'facility': 'Fondazione Santa Lucia IRCCS', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '00186', 'city': 'Rome', 'state': 'Lazio', 'country': 'Italy', 'facility': 'Ospedale San Giovanni Calibita Fatebenefratell;Neurologia', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '08661', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': 'Vilnius University Hospital Santariskiu Clinic', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '80020', 'city': 'Culiacán', 'country': 'Mexico', 'facility': 'Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC', 'geoPoint': {'lat': 24.80209, 'lon': -107.39421}}, {'zip': '64460', 'city': 'Monterrey', 'country': 'Mexico', 'facility': 'Hospital Uni; Dr. Jose E. Gonzalez', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'zip': '64710', 'city': 'Monterrey', 'country': 'Mexico', 'facility': 'AVIX Investigación Clínica S.C', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'zip': '25000', 'city': 'Saltillo', 'country': 'Mexico', 'facility': 'Hospital Universitario de Saltillo', 'geoPoint': {'lat': 25.42595, 'lon': -100.97963}}, {'zip': '01-684', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Centrum Medyczne NeuroProtect', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '420021', 'city': "Kazan'", 'country': 'Russia', 'facility': 'State Autonomous Healthcare Institution "Republican Clinical Neurological Center', 'geoPoint': {'lat': 55.78874, 'lon': 49.12214}}, {'zip': '420101', 'city': "Kazan'", 'country': 'Russia', 'facility': 'State autonomous institution of healthcare Inter-regional clinical and diagnostic center', 'geoPoint': {'lat': 55.78874, 'lon': 49.12214}}, {'zip': '190121', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'SHI City Psychoneurological Dispensary #7 (with Hospital)', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '22332', 'city': 'Incheon', 'country': 'South Korea', 'facility': 'Inha University Hospital', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'zip': '05030', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Konkuk University Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '07985', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Ewha Womans University Mokdong Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '08034', 'city': 'BArcelon', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Fundació ACE'}, {'zip': '8195', 'city': 'Sant Cugat del Vallès', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital General De Catalunya; Servicio de Neurologia', 'geoPoint': {'lat': 41.47063, 'lon': 2.08611}}, {'zip': '08222', 'city': 'Terrassa', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Mutua De Terrasa; Servicio de Neurologia', 'geoPoint': {'lat': 41.56667, 'lon': 2.01667}}, {'zip': '10600', 'city': 'Plasencia', 'state': 'Caceres', 'country': 'Spain', 'facility': 'Hospital Virgen del Puerto. Servicio de Neurología', 'geoPoint': {'lat': 40.03116, 'lon': -6.08845}}, {'zip': '31008', 'city': 'Pamplona', 'state': 'Navarre', 'country': 'Spain', 'facility': 'Clinica Universitaria de Navarra; Servicio de Neurología', 'geoPoint': {'lat': 42.81687, 'lon': -1.64323}}, {'zip': '28041', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario 12 de Octubre; Servicio de Neurologia', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '55139', 'city': 'Samsun', 'country': 'Turkey (Türkiye)', 'facility': 'Ondokuz Mayis Univ. Med. Fac.; Neurology', 'geoPoint': {'lat': 41.27976, 'lon': 36.3361}}, {'zip': 'KT16 0AE', 'city': 'Chertsey', 'country': 'United Kingdom', 'facility': 'Surrey and Borders NHS Foundation Trust; Research and Development Departmant; Abraham Cowley Unit', 'geoPoint': {'lat': 51.38812, 'lon': -0.50782}}, {'zip': 'W6 8RF', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Charing Cross Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'overallOfficials': [{'name': 'Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Hoffmann-La Roche'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}